- Home
- VPG vs RIGL Comparison
VPG vs RIGL Comparison
Compare VPG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VPG
- RIGL
- Stock Information
- Founded
- VPG 2009
- RIGL 1996
- Country
- VPG United States
- RIGL United States
- Employees
- VPG N/A
- RIGL N/A
- Industry
- VPG Electrical Products
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- VPG Technology
- RIGL Health Care
- Exchange
- VPG Nasdaq
- RIGL Nasdaq
- Market Cap
- VPG 340.4M
- RIGL 335.5M
- IPO Year
- VPG N/A
- RIGL 2000
- Fundamental
- Price
- VPG $28.45
- RIGL $38.85
- Analyst Decision
- VPG
- RIGL Buy
- Analyst Count
- VPG 0
- RIGL 5
- Target Price
- VPG N/A
- RIGL $38.20
- AVG Volume (30 Days)
- VPG 103.9K
- RIGL 995.6K
- Earning Date
- VPG 08-05-2025
- RIGL 08-05-2025
- Dividend Yield
- VPG N/A
- RIGL N/A
- EPS Growth
- VPG N/A
- RIGL N/A
- EPS
- VPG N/A
- RIGL 5.43
- Revenue
- VPG $295,282,000.00
- RIGL $267,921,000.00
- Revenue This Year
- VPG N/A
- RIGL $59.93
- Revenue Next Year
- VPG $5.48
- RIGL N/A
- P/E Ratio
- VPG N/A
- RIGL $7.15
- Revenue Growth
- VPG N/A
- RIGL 105.62
- 52 Week Low
- VPG $18.57
- RIGL $12.66
- 52 Week High
- VPG $30.11
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- VPG 54.91
- RIGL 68.57
- Support Level
- VPG $28.22
- RIGL $39.00
- Resistance Level
- VPG $29.81
- RIGL $42.08
- Average True Range (ATR)
- VPG 0.87
- RIGL 2.32
- MACD
- VPG 0.15
- RIGL -0.37
- Stochastic Oscillator
- VPG 62.29
- RIGL 53.26
About VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.